

DATE:	25 May 2026
TO:	All Zones
FROM:	Biochemical Genetics Laboratories, Genetics and Genomics, APL
RE:	Discontinuation of Urine Sulfite Screen Testing

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- Effective May 26, 2026, the Sulfite Screen performed within the North and South Biochemical Genetics Laboratories will be discontinued.
- This testing will be replaced by referral of urine specimens for S-Sulfocysteine Panel testing performed by Mayo Clinic Laboratories.

Background

- The Sulfite Screen has historically been available within the North and South Biochemical Genetics Laboratories as a front-line screen for suspected Sulfite Oxidase and Molybdenum Cofactor Deficiencies.
- The test consists of a urine dipstick requiring freshly collected urine.
- Urine sulfite is highly unstable and prone to rapid degradation; the assay is known to have limited sensitivity, particularly in dilute urine samples, and only a 1-2 hour stability window.
- The S-Sulfocysteine Panel test, quantitatively measuring S-sulfocysteine as well as hypoxanthine, xanthine and uric acid, provides a more sensitive and comprehensive test with a specimen stability window of 90 days when frozen.

How this will impact you

- Sulfite Screen [LAB4042] will be discontinued, and the corresponding order set will be removed from EPIC.
- Physicians requiring evaluation of suspected Sulfite Oxidase or Molybdenum Cofactor Deficiencies should order S-Sulfocysteine Panel (Referred Test) [LAB9982].

Action Required

Physicians: Remove **Sulfite Screen [LAB4042]** from personal preference lists within **EPIC**.

Effective **May 26, 2026**

Questions/Concerns

- Dr. David Sinasac, Biochemical Geneticist, Lab Head for Biochemical Genetics South Laboratory.
Email: David.Sinasac@albertaprecisionlabs.ca
- Dr. Iveta Sosova, Biochemical Geneticist, Lab Head for Biochemical Genetics North Laboratory
Email: Iveta.Sosova@albertaprecisionlabs.ca

Approved by

- Dr. Lauren MacNeil, Program Medical Lead, Genetics & Genomics North, APL
- Dr. Jillian Parboosingh, Program Medical Lead, Genetics & Genomics South, APL
- Dr. Carolyn O'Hara, Chief Medical Laboratory Officer (Interim), APL